# Differences in the Eradication of Helicobacter Pylori by Different Therapies

> **NCT05097846** · NA · UNKNOWN · sponsor: **wang xiaoyan** · enrollment: 100 (estimated)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Group1 Vonoprazan Fumarate + amoxicillin + doxycycline
- **DRUG:** Group2 Vonoprazan Fumarate + furazolidone + doxycycline
- **DRUG:** Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
- **DRUG:** Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline

## Key facts

- **NCT ID:** NCT05097846
- **Lead sponsor:** wang xiaoyan
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-17
- **Primary completion:** 2022-06-17
- **Final completion:** 2022-10-17
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05097846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05097846, "Differences in the Eradication of Helicobacter Pylori by Different Therapies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05097846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*